Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "upadacitinib"

13 News Found

USFDA approves Rinvoq as an oral treatment for ankylosing spondylitis
Drug Approval | May 01, 2022

USFDA approves Rinvoq as an oral treatment for ankylosing spondylitis

The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases

AbbVie and Allergan Aesthetics to present new research at 2022 AAD annual meeting
Biotech | March 22, 2022

AbbVie and Allergan Aesthetics to present new research at 2022 AAD annual meeting

Twelve abstracts and two late-breaking presentations demonstrate AbbVie and Allergan Aesthetics' shared commitment to advancing research across a spectrum of dermatologic conditions and aesthetic indications

USFDA approves Rinvoq for ulcerative colitis
Drug Approval | March 17, 2022

USFDA approves Rinvoq for ulcerative colitis

First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology

Latest Stories

Kahimmune Therapeutics signs agreement for scientific collaboration with Gustave Roussy

Leinco Technologies and CellCarta partner to advance proteomics in immuno-oncology

Sanofi Consumer Healthcare reports 33% revenue growth in Q1 FY26; PAT rises 36%

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics
Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics
Dr Maloy Ghosh Chief Scientific Officer, Zumutor Biologics
The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings
The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings
Venkat Nelabhotla Co-Founder, President & CEO, Vyome Holdings, Inc.
Local manufacturing, deeper CDMO ties, region-specific solutions remain our top priorities in next 3–5 years: Ganesh Bade, Director Bioprocessing–IMEA, Avantor
Local manufacturing, deeper CDMO ties, region-specific solutions remain our top priorities in next 3–5 years: Ganesh Bade, Director Bioprocessing–IMEA, Avantor
Ganesh Bade Head Bioprocessing, India, Avantor

Packaging